antiemetic drug research has resulted in the introduction of the second-generation 5-hydroxytryptamine-3 (5-ht3) receptor antagonist palonosetron and the neurokinin-1 (nk-1) receptor antagonist aprepitant, as well as new data on existing antiemetics.